Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpibectir - BioVersys/GSK

Next Previous
Drug Profile

Alpibectir - BioVersys/GSK

Alternative Names: BVL-GSK-098; BVL-GSK3729098

Latest Information Update: 01 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioVersys; GlaxoSmithKline
  • Developer BioVersys
  • Class Antituberculars; Small molecules
  • Mechanism of Action Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tubercular meningitis; Tuberculosis

Most Recent Events

  • 27 Dec 2024 BioVersys plans a phase II trial for Tuberculosis (Newly diagnosed, Combination therapy) (PO) in January 2025 (NCT06748937)
  • 28 Oct 2024 No recent reports of development identified for phase-I development in Tuberculosis(In volunteers) in Spain (PO, Capsule)
  • 16 Oct 2024 BioVersys completes a phase-II clinical trials in Tuberculosis (Combination therapy, Newly diagnosed, Treatment-naïve) in South Africa (PO), prior to October 2024 (NCT05473195)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top